Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.
Analyst Ratings
This is a breakdown of recent recommendations for Monte Rosa Therapeutics and Lexeo Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monte Rosa Therapeutics | 0 | 1 | 3 | 0 | 2.75 |
| Lexeo Therapeutics | 0 | 0 | 5 | 1 | 3.17 |
Monte Rosa Therapeutics presently has a consensus target price of $15.25, indicating a potential upside of 126.60%. Lexeo Therapeutics has a consensus target price of $23.80, indicating a potential upside of 665.27%. Given Lexeo Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Monte Rosa Therapeutics.
Volatility & Risk
Institutional & Insider Ownership
80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 6.5% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Monte Rosa Therapeutics and Lexeo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monte Rosa Therapeutics | N/A | -62.68% | -38.83% |
| Lexeo Therapeutics | N/A | -57.66% | -48.18% |
Earnings and Valuation
This table compares Monte Rosa Therapeutics and Lexeo Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Monte Rosa Therapeutics | $14.98 million | 27.61 | -$135.35 million | ($1.83) | -3.68 |
| Lexeo Therapeutics | $650,000.00 | 158.21 | -$66.39 million | ($3.16) | -0.98 |
Lexeo Therapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Lexeo Therapeutics beats Monte Rosa Therapeutics on 9 of the 14 factors compared between the two stocks.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
